Sorry, you need to enable JavaScript to visit this website.
Home About Partners Research and Business Development Partnerships Medicine Design

Medicine Design

We are interested in establishing alliances to develop and access novel:

Medicinal Chemistry Synthesis Technology

  • Synthetic technologies that can accelerate the delivery of API
  • Flow chemistry approaches that enable mg to kg scale
  • Efficient scale-up (kg) capabilities for photo redox chemistry
  • Chemical transformations via biocatalysis
  • Synthetic methodologies for late stage diversification
  • Synthetic methodology to access small conformationally constrained multifunctional templates
  • Monomers and building blocks in drug-like property space
  • High-throughput optimization capabilities for synthetic transformations and biocatalysis
  • Innovative capabilities for parallel medicinal chemistry

Medicinal Chemistry

  • Approaches to expand NCE target space – RNA splicing or translational modulation, orally bioavailable or CNS-penetrant protein degradation, non-CRBN and non-VHL mediated strategies for targeted protein degradation, covalent inhibition, modulation of protein-protein interactions and non-Ro5 compounds
  • Solute ligand carrier, transcription factor, deubiquitylating (DUB) enzyme, phosphatase, RNA binding protein, and biomolecular condensate modulator design and screening technologies
  • AI/ML methodologies to predict novel protein or RNA structures
  • Membrane protein structural biology technologies and capabilities, including ion channels, GPCRs and solute carrier proteins
  • DNA-compatible synthetic protocols and DNA backbone modifications that expand currently available methodology for DNA-encoded libraries (DEL)
  • Computational methods for quantitative affinity prediction and molecular dynamics simulation
  • Technologies to identify hits through virtual screening of very large compound collections
  • Ligand-based multi-parametric generative design platforms
  • Systems/chemical biology technologies enabling mechanism determination for phenotypic screening hits
  • Morphological or transcriptional profiling technologies to enable hit expansion and pathway inferences for phenotypic screening
  • Functional genomic and iPSC technology to enable facile generation of disease relevant cell systems for phenotypic screening

Pharmacokinetics Dynamics and Metabolism (PDM)

  • Translation
    • Translational modeling and simulation approaches, systems pharmacology/PK-PD; deep knowledge of targets/pathways; increased confidence in target drug selection
  • Bioanalysis and biomarkers
    • Novel bioanalytical and cellular imaging techniques
    • Specific biomarkers of ADME DDI liability (both transporter and enzyme biomarkers)
    • Novel methodology for pull-down of tissue specific exosomes
  • Disposition and delivery of therapies
    • Novel commercially viable delivery technologies (oral and non-oral, including topical)
    • Biodistribution of nanoparticles at whole organ and cellular level
  • Targeting, prediction and modeling of transporter-mediated disposition and DDIs – small molecules
    • Quantitation and scaling of transporters for input into physiological PK models of tissue penetration and clearance including biliary clearance
    • Determination of intracellular/sub-cellular unbound concentrations of transported drugs
  • Novel approaches to achieving selective tissue distribution (including receptor mediated and transporter mediated strategies)
  • Transformative in vitro assays such as PK on a chip
  • Technologies that enable tissue specificity and therapeutic window enablement
  • PBPK to predict clinical DDI